The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression

Estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative, or “triple negative,” breast cancer (TNBC) is a poor prognosis clinical subtype that occurs more frequently in younger women and is commonly treated with toxic chemotherapy. Effective targeted therapy for TNBC is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazumdar, Abhijit, Tahaney, William M., Reddy Bollu, Lakshmi, Poage, Graham, Hill, Jamal, Zhang, Yun, Mills, Gordon B., Brown, Powel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659706/
https://www.ncbi.nlm.nih.gov/pubmed/31372497
http://dx.doi.org/10.1038/s41523-019-0118-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659706/
https://www.ncbi.nlm.nih.gov/pubmed/31372497
http://dx.doi.org/10.1038/s41523-019-0118-6

Ejemplares similares